Overview

Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens
Phase:
Phase 3
Details
Lead Sponsor:
Sprout Pharmaceuticals, Inc